프레스티지바이오파마

950210KOSPISector: Pharma & Biotech

₩5,030▼ 3.45%Market cap ₩302.3BAs of Jul 21, 2026 close · updated once daily

Grade C43.4 ptsTop 65% of 2,523 stocks

Financial strength

42.6

Growth momentum

63.6

Price attractiveness

29.9

As of Jul 21, 2026 close · This grade is not a buy/sell recommendation — it is information mechanically scored from public data using a fixed formula.

Financial strength

42.6

How much debt does it carry relative to equity?

Debt-to-equity ratio

46.7%

✓ Above median · Top 45.7% in sector

Sector median 51.5%

Can it cover what's due within a year?

Current ratio

127.0%

✗ Below median · Top 65.2% in sector

Sector median 191.3%

How much of revenue becomes profit?

Operating margin

-470.1%

✗ Below median · Top 91.2% in sector

Sector median -2.3%

How much did it earn on its own capital?

ROE (return on equity)

5.2%

✓ Above median · Top 27.4% in sector

Sector median -4.5%

Source filing: annual report (consolidated) — view original ↗

Growth momentum

63.6

How much did revenue grow in a year?

Revenue growth (YoY)

1875.4%

✓ Above median · Top 0.7% in sector

Sector median 6.4%

Did core profits grow in a year?

Operating income change (YoY)

-1.9%

✗ Below median · Top 56.5% in sector

Sector median 3.6%

Are core profits higher than three years ago?

Operating income change (3Y)

1.4%

✗ Below median · Top 51.9% in sector

Sector median 3.5%

Source filing: annual report (consolidated) — view original ↗

Price attractiveness

29.9

Is the price expensive relative to earnings?

P/E (price-to-earnings)

18867.9x

✓ Above median · Top 42.5% in sector

Sector median P/E of profitable peers 14.4x · 57% loss-making

Is the price expensive relative to book value?

P/B (price-to-book)

1000.00x

✗ Below median · Top 97.8% in sector

Sector median 1.39x

Valuation uses the Jul 21, 2026 close and market cap

Grade distribution of 248 stocks in Pharma & Biotech

S1A52B66C51D61F15